Chemo intranipple injection may help target milk ducts to treat breast cancer; FDA accepts BioDelivery's Bunavail NDA for opioid dependence;

> Boston researchers are looking to target milk ducts to fight breast cancer with an intranipple injection of chemotherapy, delivering drugs directly to the root of many forms of the disease. Story

> The FDA accepted an NDA from BioDelivery Sciences ($BDSI) for the company's Bunavail opioid-dependence treatment, which uses BioDelivery's BioErodible MucoAdhesive delivery technology to treat cancer pain. More

> Dicerna Pharmaceuticals presented proof-of-concept data to support the slicing of oncogenes in the company's approach to RNAi treatments. Release

> 3M Drug Delivery Systems will manufacture ProStrakan Group's Sancuso transdermal patch in Europe with recent EMA approval. Worn under the arm, Sancuso controls chemotherapy-induced nausea and vomiting. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.